Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist*

Tumor necrosis factor-α (TNF) induces inflammatory response predominantly through the TNF receptor-1 (TNFR1). Thus, blocking the binding of TNF to TNFR1 is an important strategy for the treatment of many inflammatory diseases, such as hepatitis and rheumatoid arthritis. In this study, we identified a TNFR1-selective antagonistic mutant TNF from a phage library displaying structural human TNF variants in which each one of the six amino acid residues at the receptor-binding site (amino acids at positions 84-89) was replaced with other amino acids. Consequently, a TNFR1-selective antagonistic mutant TNF (R1antTNF), containing mutations A84S, V85T, S86T, Y87H, Q88N, and T89Q, was isolated from the library. The R1antTNF did not activate TNFR1-mediated responses, although its affinity for the TNFR1 was almost similar to that of the human wild-type TNF (wtTNF). Additionally, the R1antTNF neutralized the TNFR1-mediated bioactivity of wtTNF without influencing its TNFR2-mediated bioactivity and inhibited hepatic injury in an experimental hepatitis model. To understand the mechanism underlying the antagonistic activity of R1antTNF, we analyzed this mutant using the surface plasmon resonance spectroscopy and x-ray crystallography. Kinetic association/dissociation parameters of the R1antTNF were higher than those of the wtTNF, indicating very fast bond dissociation. Furthermore, x-ray crystallographic analysis of R1antTNF suggested that the mutation Y87H changed the binding mode from the hydrophobic to the electrostatic interaction, which may be one of the reasons why R1antTNF behaved as an antagonist. Our studies demonstrate the feasibility of generating TNF receptor subtype-specific antagonist by extensive substitution of amino acids of the wild-type ligand protein.

[1]  R. Zinkernagel,et al.  Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes , 1993, Nature.

[2]  W. Fiers,et al.  Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma , 1992, The Journal of experimental medicine.

[3]  P. Young,et al.  Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth* , 1998, The Journal of Biological Chemistry.

[4]  Edward Y. Kim,et al.  TNF Receptor Type 2 (p75) Functions as a Costimulator for Antigen-Driven T Cell Responses In Vivo1 , 2006, The Journal of Immunology.

[5]  R. Gaynor,et al.  Identification of NF-κB-regulated genes induced by TNFα utilizing expression profiling and RNA interference , 2003, Oncogene.

[6]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[7]  M. Greene,et al.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.

[8]  B. Ryffel,et al.  Membrane TNF confers protection to acute mycobacterial infection , 2005, Respiratory research.

[9]  Najia Shakoor,et al.  Drug-induced systemic lupus erythematosus associated with etanercept therapy , 2002, The Lancet.

[10]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[11]  B. Aggarwal,et al.  Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon , 1985, Nature.

[12]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[13]  P. Angus,et al.  Hepatitis B and C virus infections and anti‐tumor necrosis factor‐α therapy: Guidelines for clinical approach , 2006, Journal of gastroenterology and hepatology.

[14]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[15]  M. Chen,et al.  Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. , 1992, The Journal of biological chemistry.

[16]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[17]  H. Loetscher,et al.  Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55 , 1993, The Journal of experimental medicine.

[18]  Peter Scheurich,et al.  Control of Receptor-induced Signaling Complex Formation by the Kinetics of Ligand/Receptor Interaction* , 2002, The Journal of Biological Chemistry.

[19]  J. Cyster,et al.  Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. , 2001, Immunity.

[20]  N. Sicotte,et al.  Onset of multiple sclerosis associated with anti-TNF therapy , 2001, Neurology.

[21]  D. Underwood,et al.  Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[23]  B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[24]  Pascal Schneider,et al.  A secreted high-affinity inhibitor of human TNF from Tanapox virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  George Kollias,et al.  Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.

[26]  P. Scheurich,et al.  Tumor necrosis factor (TNF) receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1 , 1998, European journal of immunology.

[27]  P. Lipsky,et al.  New concepts in the treatment of rheumatoid arthritis. , 2003, Annual review of medicine.

[28]  H. Holtmann,et al.  Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. , 1990, The Journal of biological chemistry.

[29]  Warwick J. Britton,et al.  Transmembrane TNF Is Sufficient to Initiate Cell Migration and Granuloma Formation and Provide Acute, but Not Long-Term, Control of Mycobacterium tuberculosis Infection1 , 2005, The Journal of Immunology.

[30]  McFARLAN Am,et al.  Poliomyelitis and tonsillectomy. , 1948 .

[31]  W. Lesslauer,et al.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. , 1996, Journal of immunology.

[32]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[33]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[34]  S. Nakashima,et al.  Lethal hepatic apoptosis mediated by tumor necrosis factor receptor, unlike Fas-mediated apoptosis, requires hepatocyte sensitization in mice. , 1999, Journal of hepatology.

[35]  Y. Tsutsumi,et al.  Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. , 1995, British Journal of Cancer.

[36]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[37]  J. Nagakawa,et al.  Involvement of tumor necrosis factor‐α in development of hepatic injury in galactosamine‐sensitized mice , 1990, Hepatology.

[38]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[39]  R. Guler,et al.  Transmembrane TNF Induces an Efficient Cell-Mediated Immunity and Resistance to Mycobacterium bovis Bacillus Calmette-Guérin Infection in the Absence of Secreted TNF and Lymphotoxin-α1 , 2002, The Journal of Immunology.

[40]  William B. Smith,et al.  Dissociation of TNF‐alpha cytotoxic and proinflammatory activities by p55 receptor‐ and p75 receptor‐selective TNF‐alpha mutants. , 1994, The EMBO journal.

[41]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[42]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[43]  D. Thiele,et al.  The role of TNF–TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection , 2003, Journal of leukocyte biology.

[44]  Xiaowei Xu,et al.  Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Y. Yoshioka,et al.  Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting , 2003, Nature Biotechnology.

[46]  M. Feldmann,et al.  TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases , 2003, Nature Medicine.

[47]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[48]  G. Wong,et al.  TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.

[49]  M. Leist,et al.  Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. , 1995, Journal of immunology.